ClinicalTrials.gg
RecruitingNCT07949916MS and TBE vacUpdated Nov 19, 2026

Immunogenicity and Safety of Vaccination Against Tick Borne Encephalitis (TBE) in Patients Living With Multiple Sclerosis (MS)

An observational study in Multiple Sclerosis, sponsored by Insel Gruppe AG, University Hospital Bern. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Insel Gruppe AG, University Hospital Bern · Observational

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.
Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 143 studies in Multiple Sclerosis with a site in Switzerland — 25 open to participants now, 37 under way, 8 of them phase 3. Multiple Sclerosis · Switzerland.

Planned enrollment
42nd of 57
50 · median 182
Started
2026
with 7 others
Observational
57 of 143
13 open now
Primary completion
2027-05
later than 9 of 36 live
Registered
140th of 143
by date
Lead sponsor
9 of 143
Insel Gruppe AG, University Hospital Bern

Among the 143 studies in Multiple Sclerosis with a site in Switzerland, this one is the 42nd largest by planned enrollment of the 57 observational ones that give a count, is one of 8 that started in 2026, is one of 57 observational ones, reaches primary completion later than 9 of the 36 other live ones, and was the 140th registered.

Multiple Sclerosis

3,272 studies on the registry are indexed under Multiple Sclerosis; 664 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

25 of the 143 studies in Multiple Sclerosis with a site in Switzerland are open now. Recruiting first, the newest first:

19 more — sign in →

All 25 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 432 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 213 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 143 studies in Multiple Sclerosis with a site in Switzerland, or all of them as a file.
02

Study summary

This is a monocenter, prospective cohort study. The study investigates the response of patients living with multiple sclerosis (MS) to vaccination against tick-borne viral encephalitis (TBE).

The prevalence of TBE has increased significantly in Switzerland over the past two decades. Whereas previously only the lowland regions of northern Switzerland and the Aare Valley were considered areas where TBE vaccination was indicated, the disease is now endemic throughout Switzerland (except for Ticino). Since TBE specifically affects the nervous system, there is a clear indication for vaccination, particularly for people whose nervous system is already compromised.

MS is the most common neurological autoimmune disease among young adults in northern latitudes. It is a progressive disease characterized by a gradual deterioration of neurological functions. The course of the disease can be slowed through immunomodulatory therapies. However, these therapies also lead to a certain degree of immunosuppression, which may reduce the immune response to vaccinations. At the same time, some people with MS experience fear or scepticism towards vaccinations, as infections often lead to a worsening of symptoms or can trigger a relapse. Since vaccinations mimic an infection to some extent, this concern is sometimes transferred to vaccinations as well.

The study hypothesizes that the TBE vaccine in people living with MS on non-B-cell depleting treatment shows adequate immunogenicity.

Moreover, the study will assess the safety of TBE vaccination.

03

Conditions studied

  • Multiple Sclerosis

Keywords

  • tick borne encephalitis
  • Multiple sclerosis
  • Vaccination
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The investigators target a sample size of 50 people living with MS with stable RRMS (no evidence of disease activity -NEDA-3 status - as defined by no clinical relapse, no EDSS worsening and no new MS-lesions on MRI) for ≥ 1 year prior to inclusion into the study and treated with non-B-cell depleting therapies for at least 6 months in monotherapy.

In order to have a homogenous and stable patient population, the investigators decided to include only patients without evidence of disease activity for at least 1 year prior to inclusion. Considering the latter the investigators classify any disease reactivation during the period of 42 days (+/- 7days) after the first dose / booster dose as related to the intervention (vaccination).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult (≥ 18 years old)
  • Suspected neuroimmunological disorder with CNS affection

    • including suspicion of Multiple Sclerosis (MS)
    • Diagnosed Multiple Sclerosis (MS)
    • Clinically Isolated Syndrome
    • Radiologically Isolated Syndrome
  • stable RRMS - defined as no evidence of disease activity-NEDA-3 status-as defined by no clinical relapse, no EDSS worsening and no new MS-lesions on MRI for ≥ 1 year prior to inclusion
  • treated with non-B-cell depleting therapies for at least 6 months in monotherapy
  • TBE vaccine:

    • never been vaccinated against TBE or
    • clinical indication for booster vaccination (person living with MS and has had primary series of 3 vaccines of which the last one was ≥ 10 years ago)
  • Provided written

Exclusion criteria

Exclusion Criteria

  • Any B-cell depleting therapies in last 12 months prior to recruitment
  • Any other vaccination in last 2 months prior to recruitment
  • Any foreseeable and necessary other vaccination up to 42 days post dose 1
  • Immunoglobulin-Infusion (intravenous or subcutaneous, IVIG or SCIG) in the last 4 months prior to the drawing of study samples
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Target follow-up
7 Months
Patient registry
Yes

Groups and cohorts

  • Primary vaccination series or Booser against TBE in patients with MS

    According to Swiss guidelines, patients with MS will receive the primary vaccination series (3 doses) against TBE (if they have never been vaccinated) or a TBE booster (if they have already received the primary vaccination series and their last vaccination was ≥ 10 years ago).

06

What researchers measure

Primary outcomes

  1. Primary immunogenicity endpoint

    Change in antibody concentration (GMC) from baseline to day 42 post dose 1 as measured by ELISA

    Time frame: 42 days post dose 1

Secondary outcomes

  1. Immunogenicity endpoint

    Change in antibody titers as measured by serum neutralizing test (SNT) from baseline to day 42 (post dose 1)

    Time frame: 42 days post dose 1

  2. Immunogenicity endpoint

    Change in antibody titers as measured by ELISA from baseline to week 9 and month 7 post dose 1 if primary vaccination resp. from baseline to month 6 post booster dose.

    Time frame: 7 months post dose 1 or 6 months post booster dose

  3. Immunogenicity endpoint

    Change in antibody titers as measured by SNT from baseline to week 9 and month 7 post dose 1 if primary vaccination resp. from baseline to month 6 post booster dose.

    Time frame: 7 months post dose 1 or 6 months post booster dose

  4. Immunogenicity endpoint

    Seropositivity as measured by ELISA . Seropositivity is defined as IgG antibody concentration \>150 U/ml for ELISA.

    Time frame: at each time point (7 months)

  5. Immunogenicity endpoint

    Seropositivity as measured by SNT at each time point. Seropositivity is defined as antibody titer \>1:10 for SNT.

    Time frame: at each time point (7 months)

  6. Safety endpoint

    The investigators will analyse indicators of disease activity through different indicators only up to day 42 (+/-7d) post dose 1 \- Incidence of MS-relapses - defined clinically, according to clinical expert judgement, by the presence of MS-typical symptoms with objectifiable findings lasting more than 24 hours, without fever or infection.

    Time frame: 42 (+/-7d) post dose 1

  7. Safety endpoint

    The investigators will analyse indicators of disease activity through different indicators only up to day 42 (+/-7d) post dose 1 \- Activity in cerebral MRI scan (new or enlarging lesions or gadolinium uptake)

    Time frame: 42 (+/-7d) post dose 1

  8. Safety endpoint

    The investigators will analyse indicators of disease activity through different indicators only up to day 42 (+/-7d) post dose 1 \- Neurological assessment (EDSS)

    Time frame: 42 (+/-7d) post dose 1

  9. Safety endpoint

    The investigators will analyse indicators of disease activity through different indicators only up to day 42 (+/-7d) post dose 1 \- Multivariable blood biomarker based scores for MS disease activity (MSDA) and disease pathways (Octave Bioscience, USA)

    Time frame: 42 (+/-7d) post dose 1

  10. Safety endpoint

    The investigators will analyse indicators of disease activity through different indicators only up to day 42 (+/-7d) post dose 1 \- Vaccine reactogenicity (solicited and unsolicited local and systemic vaccine reactions)

    Time frame: 42 (+/-7d) post dose 1

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for May 2027, 13 months after the start.

Of 335 non-industry observational studies under Multiple Sclerosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 81. This study's planned 13 months is below that.

Counting every sponsor, half of 426 studies reached it within 41 months; a quarter within 15 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2026
First posted
Nov 19, 2026
StartActual
Apr 22, 2026
Primary completionEst.
May 31, 2027
CompletionEst.
May 31, 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07949916
Responsible party
Sponsor
First posted
Nov 19, 2026
Start date
Apr 22, 2026
Primary completion
May 31, 2027 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Cornelia Staehelin, PD. Dr. med.
Contact
cornelia.staehelin@insel.ch
31 632 01 83 ext. +41
Robert Hoepner, Prof. Dr. med.
Contact
robert.hoepner@insel.ch
316325835 ext. +41

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion